Home Cart Sign in  
Chemical Structure| 56390-09-1 Chemical Structure| 56390-09-1

Structure of Epirubicin HCl
CAS No.: 56390-09-1

Chemical Structure| 56390-09-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Epirubicin HCl, a L-arabino derivative of doxorubicin, can inhibit topoisomerase and used as antineoplastic agent.

Synonyms: 4'-Epidoxorubicin hydrochloride; Epirubicin (hydrochloride); 4’-Epidoxorubicin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Epirubicin HCl

CAS No. :56390-09-1
Formula : C27H30ClNO11
M.W : 579.98
SMILES Code : O=C1C2=C(O)C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@H]4C[C@H](N)[C@@H](O)[C@H](C)O4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=O.[H]Cl
Synonyms :
4'-Epidoxorubicin hydrochloride; Epirubicin (hydrochloride); 4’-Epidoxorubicin
MDL No. :MFCD00941448

Safety of Epirubicin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Epirubicin HCl

DNA

Isoform Comparison

Biological Activity

Target
  • Topoisomerase

In Vitro:

Cell Line
Concentration Treated Time Description References
T24 cells 0.04 to 0.63 μM 48 hours To evaluate the cytotoxicity of Epirubicin on T24 cells PMC8983122
KU-7 cells 0.04 to 0.63 μM 48 hours To evaluate the cytotoxicity of Epirubicin on KU-7 cells PMC8983122
SV-huc-1 cells 0.04 to 0.63 μM 48 hours To evaluate the cytotoxicity of Epirubicin on SV-huc-1 cells PMC8983122
MCF-7 0, 1.25, 2.5, 5, or 10 µg/ml 12 h or 24 h To examine the effect of Epirubicin on MCF-7 cell proliferation, results showed that Epirubicin inhibited cell proliferation in a time- and concentration-dependent manner PMC7814033
MDA-MB-468 0, 1.25, 2.5, 5, or 10 µg/ml 12 h or 24 h To examine the effect of Epirubicin on MDA-MB-468 cell proliferation, results showed that Epirubicin inhibited cell proliferation in a time- and concentration-dependent manner PMC7814033
C6 glioma cells 0-25 μM 48 hours To evaluate the inhibitory effect of multifunctional targeting liposomes on C6 glioma cells, the results showed that the multifunctional targeting liposomes significantly inhibited the proliferation of C6 glioma cells. PMC8933639
bEnd.3 cells 10 μM 3 hours To assess the short-term cytotoxicity of drug carriers at high concentration on bEnd.3 cells, the results showed that the drug carriers significantly affected the viability of bEnd.3 cells. PMC8933639
MDA-MB-231 cells 0.1 μM 48 hours To evaluate the inhibitory effect of Epirubicin in combination with Cepharanthine on cell proliferation, the results showed that the combination significantly reduced cell viability. PMC8724299
BT549 cells 0.1 μM 48 hours To evaluate the inhibitory effect of Epirubicin in combination with Cepharanthine on cell proliferation, the results showed that the combination significantly reduced cell viability. PMC8724299
HL-1 cardiomyocytes 2 μM 12 hours To investigate the effects of Epirubicin on cardiomyocytes, results showed that Epirubicin induced ferroptosis in cardiomyocytes, and overexpression of ATP6V0A2 alleviated cell death. PMC11269639
Neonatal mouse ventricular myocytes (NMVMs) 2 μM 24 hours Through cDNA microarray analysis, it was found that ATP6V0A2 was significantly downregulated in Epirubicin-treated cardiomyocytes, further verifying its role in EIC. PMC11269639
HL-1 cardiomyocytes 1 µM 6 hours To study the effect of Epirubicin on SOCE in HL-1 cardiomyocytes, results showed that EPI significantly reduced SOCE. PMC10000558
HL-1 cardiomyocytes 1 µM 30 minutes To study the acute effect of Epirubicin on SOCE in HL-1 cardiomyocytes, results showed that EPI significantly enhanced SOCE within 30 minutes. PMC10000558
HUVEC cells 0.5 µM, 1 µM, 5 µM, 10 µM 12 hours Epirubicin caused DNA double-strand breaks, and metformin pretreatment significantly alleviated the DNA damage caused by epirubicin. PMC9820471
HUVEC cells 5 µM 6 hours Epirubicin increased ROS production, and metformin pretreatment notably reversed the ROS accumulation. PMC9820471
HUVEC cells 5 µM 24 hours Epirubicin increased Ang II release, and metformin pretreatment reduced Ang II release. PMC9820471
RAW264.7 cells 0, 1, 10, 20, 50, 100 µg/mL 24 hours To evaluate the cytotoxicity of epirubicin liposomes (EPI-SL and EPI-PL) on RAW264.7 cells. The results showed that the IC50 value of EPI-SL was 4.2 µg/mL, and the IC50 value of EPI-PL was 25 µg/mL. PMC8955061
S180 cells 0, 1, 10, 20, 50, 100 µg/mL 24 hours To evaluate the cytotoxicity of epirubicin liposomes (EPI-SL and EPI-PL) on S180 cells. The results showed that the IC50 value of EPI-SL was 7.5 µg/mL, and the IC50 value of EPI-PL was 41 µg/mL. PMC8955061

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Orthotopic bladder cancer xenograft model Intravesical instillation Once every 3 days for 3 weeks To evaluate the anti-tumor effect of Epirubicin in an orthotopic bladder cancer xenograft model PMC8983122
Wistar rats C6 glioma model tail vein injection 10 mg/kg Every 2 days for 30 days To evaluate the anti-glioma effect of multifunctional targeting liposomes in vivo, the results showed that the multifunctional targeting liposomes significantly prolonged the survival time of C6 glioma-bearing rats. PMC8933639
Nude mice MDA-MB-231 cell xenograft model Intraperitoneal injection 0.4 mg/mL Every 5 days for a total of 7 times To evaluate the effect of Epirubicin in combination with Cepharanthine on tumor volume and survival time, the results showed that the combination significantly reduced tumor volume and prolonged the survival time of mice. PMC8724299
Wistar rats C6 glioma model tail vein injection 5 mg/kg Starting from the 8th day after tumor inoculation, continuous treatment To evaluate the therapeutic effect of Epirubicin combined with Resveratrol liposomes on the C6 glioma model, the results showed that MAN and WGA-modified liposomes significantly prolonged the survival time of the animals. PMC8933639
BALB/C mice Epirubicin-induced cardiotoxicity model Tail vein injection 2 mg/kg Once every 2 days for 36 days To investigate the effects of Epirubicin on cardiac function in mice, results showed that Epirubicin reduced cardiac function, and overexpression of ATP6V0A2 improved cardiac function and alleviated myocardial fibrosis. PMC11269639
Kunming mice S180 tumor model Caudal vein injection 48 mg/kg Once weekly for 4 weeks To evaluate the anti-tumor effects of epirubicin liposomes (EPI-SL and EPI-PL) in mice of different ages. The results showed that 8-month-old mice treated with EPI-SL had significantly reduced tumor volume, no damage to healthy tissue, and a 100% survival rate. PMC8955061

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.62mL

1.72mL

0.86mL

17.24mL

3.45mL

1.72mL

References

 

Historical Records

Categories